Trial reportScientific reports2021
Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- National Heart Center Perfusion Guidelines.Saudi medical journal · 2026Guideline
- Prolonged Extracorporeal Membrane Oxygenation Without Systemic Anticoagulation in Sheep.Annals of biomedical engineering · 2026Article
- Identification of Coagulation Phenotypes Using Viscoelastic and Conventional Assays During Veno-Venous Extracorporeal Membrane Oxygenation: A Hierarchical Clustering Analysis.Artificial organs · 2026Observational
- Observational
- Thrombin generation parameters provide independent information on plasma coagulation potential in pediatric patients on extracorporeal membrane oxygenation: a prospective, single-center pilot study.Research and practice in thrombosis and haemostasis · 2026Observational
- ExtracorporeaL life support and Modification Of Hemostasis: the ELMOH trial: hemostatic changes during the first 48 h of VV- and VA-ECMO: a prospective multicenter cohort study.Critical care (London, England) · 2026Article
- Recommendations in Extracorporeal Cardiopulmonary Resuscitation Post Resuscitation Care Via An International, Modified Delphi Approach.Journal of the American Heart Association · 2026Review
- ECMO decannulation is associated with dynamic changes in coagulation profiles: an exploratory, nested cohort study.BMC anesthesiology · 2026Observational
- Mortality and complications in low-dose vs standard-dose unfractionated heparin anticoagulation for extracorporeal membrane oxygenation: a systematic review and meta-analysis.Research and practice in thrombosis and haemostasis · 2026Article
- Optimizing Drug Therapy in ECMO-Supported Critically Ill Adults: A Narrative Review and Clinical Guide.Pharmacy (Basel, Switzerland) · 2025Review
- Anticoagulation in ECMO: Target Values to Reduce Hemorrhagic Complications in Adults. A Retrospective Cohort Study.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2025Article
- Lung rehabilitation using xenogeneic cross-circulation does not lead to hyperacute rejection in a human lung transplantation model.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025Article
- Trends and outcomes of different mechanical circulatory support modalities for refractory cardiogenic shock in Takotsubo cardiomyopathy.American heart journal plus : cardiology research and practice · 2025Article
- Anticoagulation Management During ECMO: Narrative Review.JHLT open · 2025Review
- Early fluid balance and mortality following extracorporeal cardiopulmonary resuscitation: a high volume, single center study.Scandinavian journal of trauma, resuscitation and emergency medicine · 2025Observational
- Fibrinogen levels and bleeding risk in adult extracorporeal cardiopulmonary resuscitation: multicenter observational study subanalysis.Research and practice in thrombosis and haemostasis · 2025Article
- Anticoagulation and associated complications in veno-arterial extracorporeal membrane oxygenation in adult patients: A systematic review and meta-analysis.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2024Review
- Successful Microsurgical Clipping under Extracorporeal Membrane Oxygenation Treatment for a Poor-Grade Subarachnoid Hemorrhage Patient with Severe Pulmonary Neurogenic Lung.Asian journal of neurosurgery · 2024Article
- Surface Engineering for Endothelium-Mimicking Functions to Combat Infection and Thrombosis in Extracorporeal Life Support Technologies.Advanced healthcare materials · 2024Article
- Platelet Adhesion and Activation in an ECMO Thrombosis-on-a-Chip Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracorporeal membrane oxygenation (ECMO) support has a high incidence of both bleeding and thrombotic complications. Despite clear differences in patient characteristics and pathologies between veno-venous (VV) and veno-arterial (VA) ECMO support, anticoagulation practices are often the same across modalities. Moreover, there is very little data on their respective coagulation profiles and comparisons of thrombin generation in these patients. This study compares the coagulation profile and thrombin generation between patients supported with either VV and VA ECMO. A prospective cohort study of patients undergoing VA and VV ECMO at an Intensive care department of a university hospital and ECMO referral centre. In addition to routine coagulation testing and heparin monitoring per unit protocol, thromboelastography (TEG), multiplate aggregometry (MEA), calibrated automated thrombinography (CAT) and von-Willebrand's activity (antigen and activity ratio) were sampled second-daily for 1 week, then weekly thereafter. VA patients had significantly lower platelets counts, fibrinogen, anti-thrombin and clot strength with higher d-dimer levels than VV patients, consistent with a more pronounced consumptive coagulopathy. Thrombin generation was higher in VA than VV patients, and the heparin dose required to suppress thrombin generation was lower in VA patients. There were no significant differences in total bleeding or thrombotic event rates between VV and VA patients when adjusted for days on extracorporeal support. VA patients received a lower median daily heparin dose 8500 IU [IQR 2500-24000] versus VV 28,800 IU [IQR 17,300-40,800.00]; < 0.001. Twenty-eight patients (72%) survived to hospital discharge; comprising 53% of VA patients and 77% of VV patients. Significant differences between the coagulation profiles of VA and VV patients exist, and anticoagulation strategies for patients of these modalities should be different. Further research into the development of tailored anticoagulation strategies that include the mode of ECMO support need to be completed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.